Gilead Initiates Phase 1 Clinical Trial of Oral Small Molecule GLP-1 Receptor Agonist GS-4571 for Type 2 Diabetes and Obesity
Gilead Sciences
Antiviral Drug Developer
▎Armstrong
On August 21, 2024, Gilead Sciences registered a Phase I clinical trial for GS-4571 in the treatment of diabetes and obesity on the Clinicaltrials.gov website, planning to enroll 134 subjects.
According to public information released by Gilead at this year's ADA conference, GS-4571 is a small molecule GLP-1 receptor agonist.
Summary
In addition to Eli Lilly, Pfizer, Roche, AstraZeneca, Gilead Sciences, and many other multinational corporations (MNCs) have entered the small-molecule GLP-1 receptor agonist field. In China, multiple small-molecule GLP-1 receptor agonists have entered clinical stages, among which Hengrui Medicine has gone overseas through the NewCo model, and Chengyi Bio has licensed to AstraZeneca.
Comprehensive Overview of Armstrong Technology Series
A Comprehensive Review of Complement-Targeted Drug Technologies;
Complement drugs: an important direction for ophthalmic treatment;
The Landscape of Novel Macromolecular Drug Development in China;
A Comprehensive Review of China's Bispecific Antibody Technology;
A Comprehensive Review of Antengene's Pharmaceutical Technologies;
Comprehensive Overview of Harbour BioMed Technologies； Full Review of Rongchang Biotechnology； Comprehensive Review of Zai Lab's Technologies； Comprehensive Overview of WuXi Biologics； Full Review of Hengrui Medicine Technology； A Comprehensive Review of Hansoh Pharma's Technology； Comprehensive Review of Zhengda Tianqing's Technology； A Comprehensive Review of Genechem's Technology; Comprehensive Review of CStone Pharmaceuticals' Technology； Comprehensive Overview of BeiGene Technologies； Beigene Technology Full Review 2nd Edition; Comprehensive Review of Innovent Biologics Technology； Comprehensive Review of Innovent Biologics Technology, 2nd Edition； Comprehensive Review of Zhongshan Kangfang Technology； Comprehensive Review of Henlius Technologies； A Comprehensive Review of Simcere Pharmaceutical Technology； Comprehensive Overview of Junshi Biotechnology； Comprehensive Overview of Genor Biopharma； Comprehensive Overview of Zhi Dao Biotechnology； A Comprehensive Overview of Doyle Biotechnology； Comprehensive Overview of Shangjian Biotechnology; A Comprehensive Overview of Alphamab Oncology's Technology； A Comprehensive Review of Elpiscience Biopharma's Technology； Comprehensive Overview of KeyMed Technologies 2.0； Comprehensive Overview of Anerbio Technology； Comprehensive Overview of Lixun Biotechnology； Comprehensive Review of CBC Group's Technology； Yu Guoliang's Antibody Drug Layout； Full Review of Quanxin Biotechnology； Comprehensive Review of An Yuan Pharmaceutical Technology； 3SBio Technology: A Comprehensive Overview； Comprehensive Review of Renhui Biotechnology； A Comprehensive Overview of LePu Biotechnology； Comprehensive Overview of Tongrun Biotechnology； Comprehensive Review of Imeck Technology; Comprehensive Review of PegBio; Comprehensive Overview of Mabwell Biotech; Comprehensive Overview of Momenta Technology； Comprehensive Overview of NGM Technology; Comprehensive Overview of Primus Biotherapeutics； Comprehensive Overview of Primus Biotechnology 2.0; Comprehensive Overview of Clover Biotechnologies； Zelgen Pharma Antibody Drug Overview； Hengrui Medicine Antibody Drug Overview； A Comprehensive Overview of Qilu Pharmaceutical's Antibody Drugs; A Comprehensive Overview of CSPC Pharmaceutical Group's Antibody Drugs; Hansoh Pharma Antibody Drug Overview; Huahai Pharmaceutical Antibody Drug Overview； A Comprehensive Overview of Kelun Pharmaceutical's Antibody Drugs； A Comprehensive Review of Bio-Thera Technologies； Full Review of Fennec Technologies。